US 10,889,615 B2
Mutated immunoglobulin-binding polypeptides
Gustav José Rodrigo, Uppsala (SE); Tomas Bjorkman, Uppsala (SE); and Mats Ander, Uppsala (SE)
Assigned to Cytiva BioProcess R&D AB, Uppsala (SE)
Appl. No. 16/96,869
Filed by Cytiva BioProcess R&D AB, Uppsala (SE)
PCT Filed May 10, 2017, PCT No. PCT/EP2017/061162
§ 371(c)(1), (2) Date Oct. 26, 2018,
PCT Pub. No. WO2017/194596, PCT Pub. Date Nov. 16, 2017.
Application 16/096,869 is a continuation of application No. 15/282,367, filed on Sep. 30, 2016, granted, now 10,654,887.
Claims priority of application No. 1608229.9 (GB), filed on May 11, 2016; and application No. 1608232.3 (GB), filed on May 11, 2016.
Prior Publication US 2019/0144496 A1, May 16, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 1/22 (2006.01); B01J 20/26 (2006.01); C07K 14/31 (2006.01); C07K 16/00 (2006.01); B01J 20/32 (2006.01); B01J 20/285 (2006.01); B01J 20/286 (2006.01); C07K 16/12 (2006.01); C07K 17/10 (2006.01)
CPC C07K 1/22 (2013.01) [B01J 20/267 (2013.01); B01J 20/285 (2013.01); B01J 20/286 (2013.01); B01J 20/3274 (2013.01); C07K 14/31 (2013.01); C07K 16/00 (2013.01); C07K 16/1271 (2013.01); C07K 17/10 (2013.01); B01J 2220/52 (2013.01)] 54 Claims
 
1. An Fc-binding polypeptide comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), wherein the polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO:51 and SEQ ID NO:52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NOs:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine, and wherein when the polypeptide comprises SEQ ID NO:3 or SEQ ID NO:22, the asparagine residue is not mutated to histidine.